key: cord-0789447-6jo6ltty
authors: Jacquelot, Nicolas; Seillet, Cyril; Wang, Minyu; Pizzolla, Angela; Liao, Yang; Hediyeh-zadeh, Soroor; Grisaru-Tal, Sharon; Louis, Cynthia; Huang, Qiutong; Schreuder, Jaring; Souza-Fonseca-Guimaraes, Fernando; de Graaf, Carolyn A.; Thia, Kevin; Macdonald, Sean; Camilleri, Mary; Luong, Kylie; Zhang, Shengbo; Chopin, Michael; Molden-Hauer, Tristan; Nutt, Stephen L.; Umansky, Viktor; Ciric, Bogoljub; Groom, Joanna R.; Foster, Paul S.; Hansbro, Philip M.; McKenzie, Andrew N.J.; Gray, Daniel H.D.; Behren, Andreas; Cebon, Jonathan; Vivier, Eric; Wicks, Ian P.; Trapani, Joseph A.; Munitz, Ariel; Davis, Melissa J.; Shi, Wei; Neeson, Paul J.; Belz, Gabrielle T.
title: Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent anti-tumor immunity in melanoma
date: 2021-07-01
journal: Nat Immunol
DOI: 10.1038/s41590-021-00943-z
sha: bab3e0ab001a9428531360e8e15797201f4ac380
doc_id: 789447
cord_uid: 6jo6ltty

Group 2 innate lymphoid cells (ILC2) are essential to maintain tissue homeostasis. In cancer, ILC2 can harbor both pro- and anti-tumorigenic functions but we know very little about their underlying mechanisms, nor whether they could be clinically relevant or targeted to improve patient outcomes. Here, we found that high ILC2 infiltration in human melanoma was associated with a good clinical prognosis. ILC2 are critical producers of the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) which coordinate the recruitment and activation of eosinophils to enhance anti-tumor responses. Tumor-infiltrating ILC2 expressed programmed cell death protein-1 (PD-1), which limited their intratumoral accumulation, proliferation and anti-tumor effector functions. This inhibition could be overcome in vivo by combining IL-33-driven ILC2 activation with PD-1 blockade to significantly increase anti-tumor responses. Together, our results identified ILC2 as a critical immune cell type involved in melanoma immunity and revealed a potential synergistic approach to harness ILC2 function for anti-tumor immunotherapies.

The damaging effects of sun (UV) exposure constitutes a major risk factor for the development of melanoma. Control of melanoma tumor growth and suppression of transplanted tumors is thought to be mediated largely by adaptive immune cells, particularly tissue-resident CD8 + CD69 + CD103 + T RM 1, 2 . This is despite the fact that the skin also contains other immune cell types. These include innate lymphoid cells (ILCs), particularly the group 2 ILCs (ILC2s). These cells are strategically positioned to mediate immune protection against infections and skin cancers such as melanoma 3 but remain largely unexplored as a therapeutic target.

Multiple studies have shown that ILC2s accumulate in cancers. These include breast 4 , gastric 5 and pancreatic 6 cancers. They produce interleukin (IL)-4 and IL-13 which can promote the expansion of myeloid-derived suppressor cells 7 and the establishment of tumors 8 . ILC2s also secrete amphiregulin which is necessary for tissue repair and to control local inflammation 9 , but which paradoxically, can promote tissue invasion and metastasis of epidermal growth factor receptor-expressing tumors 10 . In acute promyelocytic leukemia, prostate and bladder cancers, ILC2s have been similarly shown to orchestrate an immunosuppressive tumor microenvironment which is associated with an extremely poor prognosis 7, 11 . In contrast, in pancreatic 6 , lung 12 , and colorectal 13 cancers, ILC2s were associated with increased tumor protection, enhanced anti-tumor immunity and reduced metastatic dissemination.

The role of ILC2s within the melanoma tumor environment remains enigmatic. While some studies have shown that ILC2s accumulate in melanoma tumors following IL-33 treatment and this suppressed tumor growth, decreased lung metastases and improved mouse survival 14, 15 , others suggest that IL-33-activated ILC2 also inhibit CD8 + T cell and NK cell anti-tumor functions 16, 17 . In both scenarios, pro-or anti-tumor responses have consistently been associated with increased eosinophil infiltration, mediated in part through ILC2-IL-5driven recruitment during inflammation 18 . Like ILC2, eosinophils can drive pleiotropic outcomes depending on the tumor type, but emerging evidence suggests that they may play a key role in promoting anti-tumor responses in melanoma 18, 19, 20 . Several ILC2-independent mechanisms have been described in this setting 19 , however, the cellular and molecular mechanisms that underpin ILC2-dependent eosinophil tumor infiltration and anti-tumor functions have not been fully elucidated. Indeed, the emergence of both pro-tumoral and anti-tumoral roles of ILC2 in cancer poses a major contradiction in understanding how ILC2 may be harnessed in immune therapies 21 .

Here, we show that ILC2-derived GM-CSF could drive eosinophil recruitment to melanoma tumors and enhance anti-tumor immunity. Concurrently, tumor-infiltrating ILC2 expressed PD-1 which dampened ILC2-dependent anti-tumor protection. Administration of IL-33 combined with PD-1 blockade increased ILC2 and eosinophil recruitment and enhanced anti-tumor responses. In human melanomas, gene signature mapping identified a strong correlation between the accumulation of tumor-infiltrating ILC2 and eosinophils and better survival of melanoma patients. Collectively, these data highlight mechanisms driving both pro-and anti-tumorigenic pathways within the ILC2-eosinophil axis necessary for the establishment of melanoma tumors, and identifies how targeting these pathways can be coupled to increase anti-tumor immunity.

To investigate how ILC affect melanoma formation, we first characterized ILC infiltrating tumors that develop in BRAF CA ;PTEN loxp ;Tyr::CreER T2 mice. In this strain, topical application of 4-hydroxytamoxifen induces primary malignant melanoma formation (Extended Data Fig. 1a ), mimicking human disease 22 . There was an infiltration of NK cells, ILC1, ILC2 and ILC3 within the tumor, and NK cells and ILC2 in the draining lymph nodes (Fig. 1a,b and Extended Data Fig. 1b,c) . Together with NK cells, ILC2 represented the most abundant ILC subset in tumors ( Fig. 1a and Extended Data Fig. 1c ). Next, we analyzed additional melanoma tumor models injected orthotopically into the skin of mice. Similar to the BRAF CA ;PTEN loxp ;Tyr::CreER T2 model, all ILC subsets were found to infiltrate the B16-OVA 23 and SM1WT1 24 tumors 8 and 6 days after tumor cell inoculation, respectively, and accumulated in tumor-draining lymph nodes ( Supplementary Fig. 1 ). While NK cells were the most highly represented ILC subset within these tumors, ~ 1% of the tumorinfiltrating leukocytes were non-NK ILCs ( Supplementary Fig. 1 ). Temporal analyses of Ret melanoma 25 . We then investigated ILC infiltration in two exploratory cohorts of human primary and metastatic melanoma to determine whether a similar pattern occurred in human tumors (Supplementary  Table 1 ). Using seven-color multiplex immunochemistry, we identified ILC2 within primary melanoma tumors represented ~0.2% of the CD45 + tumor immune infiltrate (Fig. 1c) , confirming that similar to preclinical mouse models, ILC2 infiltrate primary human tumors. Next, we analyzed ten metastatic tumors from stage III/IV melanoma patients (Supplementary Table 1 ) using mass cytometry ( Supplementary Fig. 2 ). This revealed that ILC1, ILC2, ILC3 and NK cells infiltrated melanoma metastases, and non-NK cell ILCs represented 0.5% of the tumor immune infiltrate (Fig. 1d) . Collectively, these results indicate that all ILC subsets infiltrate both murine and human melanoma tumors.

Next, we evaluated the requirement for individual ILC subsets in anti-melanoma immunity. Ret tumor growth and mouse survival in immunocompetent C57BL/6J mice was compared with Rag1 -/mice that lack adaptive T and B lymphocytes, and Rag2 -/-Il2rg -/mice that lack both innate and adaptive lymphoid cells. In Rag1 -/mice, Ret tumors grew quickly reaching a larger size compared with C57BL/6J mice within the first two weeks after inoculation and mice had poorer survival (Fig. 2a) , indicating that adaptive lymphocytes play an important role in immunity to melanoma as expected. However, tumors grew even more rapidly in Rag2 -/-Il2rg -/mice and mice succumbed more quickly compared with Rag1 -/mice (16 days vs 21 days) or C57BL/6J mice (27 days) (Fig. 2a) . These results suggest that ILCs are also involved in protection against melanoma.

We then investigated whether this protection was driven by a specific ILC subset. To assess the role of NK cells, which have previously shown to be involved in controlling melanoma tumor dissemination 26 , we inoculated NK cell-deficient mice, NKp46 iCre/+ Mcl1 Δ/Δ , and NKp46 iCre/+ control mice 26 with Ret tumor cells (Fig. 2b ). This showed that loss of NKp46expressing cells ( Supplementary Fig. 3 ) did not affect either the rate, or final size of tumor growth (Fig. 2b) . Similarly, loss of ILC3 in lethally-irradiated Ly5.1 + mice reconstituted with Rorc(γt) GFP/GFP (Ly5.2 + ) 27 showed no differences in tumor growth or tumor size compared with Rorc(γt) GFP/+ control chimeras (Fig. 2c) . Thus, NK cells, ILC1 and ILC3 do not appear to play a significant role in the response to primary melanoma establishment. Thus, we focused on ILC2 and used two complementary mouse models that constitutively or inducibly lacked ILC2 to investigate their role in melanoma development. Rora fl/fl mice were crossed to Il7r Cre/+ mice to inactivate the Rora gene in IL-7R-expressing cells which includes ILC2. Inoculation of Il7r Cre/+ Rora Δ/Δ mice with Ret tumor cells resulted in an increase in tumor growth compared with control Il7r +/+ Rora fl/f l littermates (Fig. 2d) supporting a key role of ILC2 in anti-tumor protection. We confirmed this observation using lethally-irradiated Il7r Cre/+ Rora Δ/Δ →Ly5.1 +/+ or C57BL/6J→Ly5.1 +/+ chimeric mice (Extended Data Fig. 3a,b) . As expected intestinal ILC2 were strongly reduced in Il7r Cre / +Rora Δ/Δ -reconstituted mice (Extended Data Fig. 3c ). Immunophenotyping of tumors at day 13 revealed a decrease of tumor-infiltrating ILC2 (Extended Data Fig. 3d ) and a trend towards reduced tumor-infiltrating CD4 + and CD8 + T cells (Extended Data Fig. 3e ). We next took advantage of the Cd4 Cre/+ Icos fl -Dtr/+ mice in which ILC2 develop normally but can be selectively ablated in vivo using diphtheria toxin (DTx) leaving the T cell compartment intact. To enhance de facto ILC2 ablation, we treated mice with recombinant murine IL-33 which increases ICOS expression in ILC2 and deletion efficiency (Extended Data Fig. 4a ).

In this setting, IL-33-treated mice had reduced tumor growth and tumor weight and increased ILC2 tumor infiltration but this did not correlate with T cell changes (Extended Data Fig. 4b -e). In contrast, DTx-depletion of ILC2 abrogated the anti-tumor effect (Extended Data Fig. 4b ,c). Thus, removal ILC2 alone appear to have an important impact on melanoma protection.

To determine whether the anti-tumor responses mediated by ILC2 were independent of other lymphoid cell subsets, purified bone marrow-derived ILC2 progenitors (ILC2p), α-lymphoid progenitors (αLP) and common lymphoid progenitors (CLP) from congenic mice were adoptively transferred into Rag2 -/-Il2rg -/recipients to allow them to replenish the lymphoid compartment 28 (Supplementary Fig. 4 ). Immune cell reconstitution was analyzed at 8 to 10 weeks after transfer ( Supplementary Fig. 5 ). CLP transfer allowed Rag2 -/-Il2rg -/-(CD45.2 + ) recipients reconstituted intestinal T and B cells and all ILC populations (CD45.1 + cells) ( Supplementary Fig. 5 ). αLP gave rise to all ILC subsets but not T or B cells while ILC2p only generated ILC2 ( Supplementary Fig. 5 ) 28 . Consistent with our earlier results (Fig. 2a) , ILCs conferred partial anti-tumor protection ( Fig. 2e and Supplementary Table 2 ). As expected, CLP transfer in Rag2 -/-Il2rg -/mice regenerated both adaptive and innate cells and fully restored anti-tumor protection similar to C57BL/6J control mice (Fig. 2e and  Supplementary Table 2 ). The transfer of αLP into Rag2 -/-Il2rg -/mice restored anti-tumor immunity to the level seen in Rag1 -/mice (Fig. 2e and Supplementary Table 2 ). However, Rag2 -/-Il2rg -/mice reconstituted with ILC2 progenitors alone exhibited anti-tumor protection. This was similar to the level of protection conferred in Rag2 -/-Il2rg -/mice reconstituted with αLP to regenerate all ILC subsets, and Rag1 -/mice (Fig. 2e and   Supplementary Table 2 ), indicating that ILC2 mediate anti-tumor immunity even in absence of other innate or adaptive lymphoid cells.

We then performed genomic analyses of human metastatic melanoma samples from the TCGA database to understand how ILC2 tumor infiltration might predict clinical outcomes. By applying machine learning approaches, we defined an ILC2 gene signature (Supplementary Table 3 ). This signature was first validated using NanoString gene expression profiling in 18 primary tumor samples for which we performed multiplex IHC analyses (Fig. 1c) and quantified ILC2 tumor infiltration (Extended Data Fig. 5a,b) . We found that the signature positively correlated with GATA3 expression together with ILC2 and Th2 cells (Extended Data Fig. 5b ) while no correlation was found with other markers or other immune cell subsets (Extended Data Fig. 5a ,b). Thus, this classifier accurately identifies enrichment of type 2 immune cells in the microenvironment. Applying the classifier to the TCGA database, we found that tumors enriched in type 2 immune cells were associated with a marked increase in overall survival of metastatic melanoma patients (Extended Data Fig. 5c ).

Collectively, these findings show that ILC2 mediate effective anti-tumor responses in melanoma and tumor enrichment in type 2 immune cells is associated with favorable outcomes in melanoma patients.

To gain insight to the mechanism by which ILC2 shape the anti-tumor immune response, we performed single-cell RNA sequencing analyses of tumor-infiltrating leukocytes (CD45 + ) isolated from BRAF CA ;PTEN loxp ;Tyr::CreER T2 mice. Tumor-infiltrating immune cells were mapped using SingleR 29 using the Immgen reference database (Fig. 3a) . We identified innate, innate-like and adaptive lymphoid populations composed of ILC2, NK cells, γδ T cells, CD8 + T cells, conventional CD4 + T cells and Tregs ( Fig. 3a and Extended Data Fig.  1c ). Immune cell subset identity was confirmed by mapping the gene expression pattern of key markers and transcription factors for T cells (Cd3d, Cd247, Cd3e, Cd3g, Cd8, Cd4, Foxp3, Rorc) and ILCs (Ncr1, Id2, Irf8, Gata3, Rora) ( Supplementary Fig. 6 ) validating the automated immune cell classification and population identification through SingleR 29 . This revealed that in addition to the well-characterized ILC2-related genes such as Il4, Il6 and Il13, approximately 30% of tumor-infiltrating ILC2 also expressed Csf2, which encodes granulocyte macrophage-colony stimulating factor (GM-CSF) (Fig. 3b ). Using intracellular cytokine staining of lung and tumors isolated from SM1WT1-, B16-OVA-and Ret-tumor bearing C57BL/6J mice, we found that ILC2, but neither T cells nor NK cells, expressed GM-CSF (Extended Data Fig. 6 and Supplementary Fig. 7 ). This is despite both cell types being previously reported as key producers of GM-CSF in autoimmune inflammatory diseases 30, 31 . Neither other immune cell subsets nor non-hematopoietic (CD45 -) cells expressed significant GM-CSF (Extended Data Fig. 6b and Supplementary Fig. 7b ,f). The frequency of IL-5-producing ILC2 in tumors and lungs were similar (Fig 3c, Extended Data Fig. 6c and Supplementary Fig. 7e-h) . However, ILC2 in tumors expressed higher levels of IL-13 and GM-CSF than lung-resident ILC2 (Fig. 3c , Extended Data Fig. 6c and Supplementary Fig. 7d ,h) with 5-20% of cells expressing all three cytokines ( Fig. 3c and Supplementary Fig. 7d,h) . Inoculation of GM-CSF-deficient (Csf2 -/-) and C57BL/6J control mice with Ret tumor cells showed that loss of GM-CSF resulted in increased tumor growth rate and tumor size (Fig. 3e ) demonstrating the requirement for GM-CSF in controlling melanoma development. To ascertain the contribution of GM-CSF production by ILC2 in anti-tumor responses, we reconstituted Rag2 -/-Il2rg -/mice with wildtype (WT) or GM-CSF (Csf2 -/-)-deficient bone marrow ILC2p (Fig. 3f) . At eight weeks these mice were inoculated with Ret tumor cells and tumors monitored (Fig. 3f ). As we previous (Fig. 2e) , anti-tumor protection was restored in Rag2 -/-Il2rg -/mice reconstituted with wildtype, but not GM-CSF-deficient, ILC2 (Fig. 3f) , indicating that ILC2-derived GM-CSF is critical to anti-melanoma immunity. Using the TCGA database, we found that metastatic tumors that expressed an imprint of type 2 immune cell infiltration also had elevated CSF2 expression compared with poorly enriched tumors (Extended Data Fig. 6d ). Furthermore, high intratumoral CSF2 expression was associated with increased overall survival (Extended Data Fig. 6e ). Collectively, these data identify that, in addition to IL-5 and IL-13, tumorinfiltrating ILC2 produce high levels of GM-CSF within the tumor microenvironment and ILC2-derived GMCSF is essential for anti-melanoma responses.

Given our earlier findings that tumor-infiltrating ILC2 abundantly produced both IL-5 and GM-CSF (Fig. 3c ,d, Extended Data Fig. 6 and Supplementary Fig. 7) , and that ILC2 were sufficient to provide an early brake on tumor growth in the absence of other ILC subsets or T or B cells ( Fig. 2e and Fig. 3f ), we hypothesized that ILC2 might regulate melanoma progression by influencing the recruitment and/or the anti-tumor function of myeloid cells. Analysis of circulating dendritic cells (DCs), monocytes and neutrophils in naive Rag1 -/-, Rag2 -/-Il2rg -/mice and Rag2 -/-Il2rg -/mice reconstituted with ILC2p showed no major differences in the prevalence of myeloid populations (Fig. 4a ). In contrast, circulating eosinophils progressively increased in ILC2-reconstituted Rag2 -/-Il2rg -/mice compared with non-reconstituted Rag2 -/-Il2rg -/mice, and reached levels similar to Rag1 -/mice 6 weeks after reconstitution (Fig. 4b ). Next we inoculated Rag1 -/-, Rag2 -/-Il2rg -/and Rag2 -/-Il2rg -/mice reconstituted with ILC2p, αLP or CLP with Ret tumor cells and enumerated tumor-infiltrating myeloid cell subsets (Fig. 4c,d) . This revealed that in ILC2p, αLPor CLP-reconstituted Rag2 -/-Il2rg -/mice which all restore ILC2 ( Supplementary Fig.   5 ), intratumoral eosinophil infiltration was replenished to the levels seen in C57BL/6J and Rag1 -/mice (Fig. 4d ). In addition, the frequency of tumor-infiltrating eosinophils was inversely correlated with the Ret tumor weight (Fig. 4e) suggesting that the ILC2-eosinophil axis may be responsible for melanoma control. In contrast, tumor-bearing Il7r Cre/+ Rora Δ/Δ (CD45.2 +/+ ) bone marrow chimeric mice showed a significant reduction in splenic and tumor-infiltrating eosinophils (Extended Data Fig. 7a -d) together with increased tumor growth rate and size (Extended Data Fig. 3b ). The number of splenic DCs, neutrophils, macrophages and other myeloid lineages were unaltered (Extended Data Fig. 7b ), while tumor-infiltrating CD103 + DCs were reduced in Il7r Cre/+ Rora Δ/Δ chimeric mice (Extended Data Fig. 7d) . Thus, to ascertain the requirement for eosinophils, eosinophil-deficient mice (Tg(Epo-DTA)#Nal, known as PHIL mice) were inoculated with Ret tumor cells. Similar to the loss of ILC2, eosinophil-deficiency ( Supplementary Fig. 8 ) led to increased tumor growth rate and size (Fig. 4f ) compared with wild-type C57BL/6J mice. Similar results were observed in an experimental lung metastasis model in eosinophil-deficient (ΔdblGATA) mice that displayed increased lung B16-F10 metastases (Fig. 4g ) and tumor burden (Fig. 4h ) compared with wild-type C57BL/6J control mice highlighting that eosinophils have antitumorigenic activities against primary and metastatic melanoma tumors. Consistent with our pre-clinical findings, in metastatic melanoma samples, we observed a highly significant correlation between tumors enriched in type 2 immune cells and eosinophil infiltration (Extended Data Fig. 8a ) and this pattern was associated with a marked improvement in patient overall survival (Extended Data Fig. 8b ).

We next analysed the frequency of circulating myeloid cells in unchallenged Rag1 -/-, Rag2 -/-Il2rg -/mice and Rag2 -/-Il2rg -/mice reconstituted with wildtype or GM-CSF deficient ILC2p 7 weeks after progenitor transfer ( Fig. 5a ,b). Consistent with our earlier results ( Fig. 4a ), Rag2 -/-Il2rg -/mice reconstituted with WT ILC2 have increased circulating eosinophils while no major changes were observed for other myeloid subsets (Fig. 5a,b) . In contrast, in Csf2 -/-ILC2-reconstituted Rag2 -/-Il2rg -/mice, an augmentation of neutrophils was seen, but no significant increase in circulating eosinophils was observed compared with Rag2 -/-Il2rg -/control mice (Fig. 5b) . We then performed in vitro analyses to determine if ILC2-derived GM-CSF expression influenced eosinophil cytotoxic functions ( Supplementary Fig. 9a ). Intestinal ILC2 purified from wild-type and Csf2 -/mice were stimulated with IL-33 for 2 days to induce IL-5 and GM-CSF secretion allowing us to generate ILC2-conditioned media ( Supplementary Fig. 9a -c). After 2 days, wild-type splenic eosinophils were cultured in complete media, or complete media plus wild-type or Csf2 -/-ILC2-conditioned media (1:1 ratio). One day later, eosinophils were harvested and analyzed by qPCR ( Fig. 5c and Supplementary Fig. 9a ). Gata2 (a master eosinophil transcription factor), Epx, Ear1 and Ear2 (encoding proteins involved in eosinophil cytotoxicity) were all increased in eosinophils in the presence of ILC2-conditioned media in the culture (Fig. 5c) . However, the enhanced Epx, Ear1 and Ear2 expression was dependent on GM-CSF in the media (Fig. 5c ). In addition, we found that GM-CSF enhanced the survival of eosinophils in vitro (Fig. 5d) . Collectively, these results indicate that ILC2-derived GM-CSF is necessary for eosinophil homeostasis and augments eosinophil activation and survival. Extending these initial findings, we found that metastatic lesions associated with improved clinical outcomes (Extended Data Fig. 8b ) exhibited a molecular signature characterized by increased CSF2, IL33, RNASE3 (ortholog of Ear1 and Ear2), TNF and IFNG gene expression (Extended Data Fig. 8c ) indicative of a pro-inflammatory/cytotoxic immune response associated with type 2 immune cells and eosinophil tumor infiltration. Thus, mapping these innate immune cell profiles in tumors provides a rationale to improve clinical prognosis of melanoma patients.

Our data show that while ILC2 play a role in restraining melanoma tumor establishment, they do not continue to accumulate over time and exhibit diminished cytokine function (Extended Data Fig. 2 ). To understand the mechanisms underpinning this switch in ILC2, we mapped immune checkpoint and co-stimulatory molecule expression in tumor-infiltrating ILCs and T cells within our single cell RNA sequencing data. We found that in addition to well-known gene-coding molecules such as Arg1 and Icos, tumor-infiltrating ILC2 also expressed Pdcd1 which encodes programmed cell death protein 1 (PD-1) (Fig. 6a) . Analyses of PD-1 protein expression showed that ILC2 expressed high levels of PD-1 (Fig. 6b -e and Supplementary Fig. 10 ), and the frequency of PD-1 + T cells and ILC2 were highly correlated ( Fig. 6b -e). Using multiplex immunohistochemical staining (Fig. 6f) , we found that ILC2 in human primary melanoma tumors also expressed high levels of PD-1 on their surface ( Fig. 6f ,g) and PD-1-expressing ILC2 were positively correlated with intratumoral PD-1-expressing T cells (Fig. 6h) . High PD-1 expression on ILC2 and T cells was also positively correlated with high expression of its ligand, PD-L1, on tumor cells (Fig. 6i ). This extends a previous observation that showed that PD-L1 + melanoma cells colocalize with cytotoxic CD8 + T cells and this was associated with favorable disease outcome 32 .

To understand how PD-1 expression might influence ILC2 function, we analyzed ILC2 in PD-1 (Pdcd1 -/-)-deficient mice at steady-state. This revealed that Pdcd1 -/mice harbored significantly higher numbers of ILC2 in the small intestine and mesenteric lymph nodes compared with wild-type controls (Extended Data Fig. 9a ,b). This accumulation was intrinsic as mixed bone marrow chimeric mice reconstituted with a 1:1 ratio of Pdcd1 -/-(CD45.2 + ):wildtype (CD45.1 + CD45.2 + ) bone marrow also showed increased ILC2 in tissues derived from the Pdcd1 -/compartment (Extended Data Fig. 9c ). Furthermore, Pdcd1 -/-ILC2 showed enhanced proliferative capacity (Extended Data Fig. 9d ). Thus, PD-1 acts as a negative regulator of ILC2 and inhibits ILC2 tissue accumulation and proliferation at steadystate.

We speculated that this impaired proliferation would impact ILC2 function in the tumor setting. Pdcd1 -/mice inoculated with Ret tumor cells showed reduced tumor growth rate and tumor size compared with wild-type controls (Fig. 7a ). This was associated with increased ILC2s and T cells in tumors ( Fig. 7b) , together with accumulation of cytokineproducing ILC2s in the tumor-draining lymph nodes of PD-1-deficient mice (Fig. 7c,d) . As expected, similar results were observed in bone marrow chimeric mice reconstituted with PD-1-deficient hematopoietic cells (Fig. 7e ,f), but surprisingly, mixed bone marrow chimeric mice (Pdcd1 -/-(CD45.2 + ):Pdcd1 +/+ (CD45.1 + CD45.2 + )→CD45.1 + recipient) exhibited similar anti-tumor-responses to chimeric mice reconstituted with PD-1-deficient cells only (Fig. 7e ,f). This favorable outcome was associated with increased intratumoral PD-1deficient ILC2 and CD8 + T cells, and enrichment of ILC2 in both the tumor-draining and contralateral lymph nodes (Fig. 7g ) similar to intact mice (Fig. 7b,c) . Given that T cells were also increased in this setting, we asked whether impaired PD-1 expression on ILC2 alone might be sufficient to enhance the anti-tumor response in vivo. Rag2 -/-Il2rg -/mice were reconstituted with wild-type or Pdcd1 -/bone marrow-derived ILC2p. Similar to our earlier results, wild-type ILC2 improved the anti-melanoma response to a level comparable to Rag1 -/mice (Fig. 7h) . However, deletion of PD-1 in ILC2 acted to further impede melanoma tumor growth (Fig. 7h) . Collectively, these results suggest that PD-1 expression negatively impacts the capacity for ILC2 to mediate anti-tumor immune responses in melanoma.

We then stimulated ILC2 with the activation cytokine IL-33 to understand whether enhanced ILC2 activation was also associated with increased PD-1 expression. In vitro IL-33 stimulation induced ILC2 expansion (Extended Data Fig. 10a,b) , particularly the inflammatory KLRG1 + subset (Extended Data Fig. 10c ) and enhanced both IL-5 and GM-CSF cytokine expression in mice (Extended Data Fig. 10d ,e) and human (Extended Data Fig. 10f ). It also significantly increased PD-1 expression on murine (Extended Data Fig.  10g ) and human (Extended Data Fig. 10h ) ILC2 indicating that activation of ILC2 drives increased PD-1 expression which then may impede ILC2 anti-tumor function in vivo.

The amplification of ILC2 combined with PD-1 upregulation that limits ILC2 function in response to IL-33 treatment prompted us to ask whether combining IL-33 with anti-PD-1 antibody could overcome the inhibitory brake of PD-1 to improve anti-tumor responses (Fig.  8a ). In vivo treatment with IL-33 or the anti-PD-1 antibody reduced Ret tumor growth rate and tumor size (Fig. 8b,c) . However, the combination of IL-33 with PD-1 blockade significantly enhanced the anti-tumor response compared with other treatment groups (Fig.  8b ,c) increasing tumor-infiltrating and splenic ILC2 (Fig. 8d ,e). While, both IL-33 and IL-33+anti-PD-1 treatments resulted in the induction of tumor-infiltrating KLRG1 + ILC2 ( Fig. 8d ,f,g), the combination therapy further increased the number and proliferation of this inflammatory ILC2 subset (Fig. 8d,h) . Neutrophils, macrophages and DCs were not increased with the combined treatment, while IL-33 alone could drive recruitment of tumorinfiltrating eosinophils and the emergence of splenic inflammatory eosinophils (Siglec-F hi ) ( Fig. 8i ,j,k,l). The frequency of both tumor-infiltrating ILC2 and eosinophils were negatively correlated with tumor weight (Fig. 8m) . Altogether, these findings demonstrate how the design of potential combination therapies such as IL-33 + anti-PD-1 can drive significantly improved anti-tumor responses that are associated with increased ILC2 and eosinophils in tumors and secondary lymphoid organs.

The melanoma tumor immune infiltrate is heterogeneous, and its composition and quality directly dictate patient outcomes 33, 34 . How individual ILC subsets contribute and can be harnessed to improve anti-tumor therapy is not yet clear. Here we show that ILC2s produce GM-CSF which drives recruitment of eosinophils and activate their effector functions to orchestrate anti-tumor immune responses. We demonstrate that activation with IL-33 dually enhanced ILC2 cytokine production and augmented PD-1-driven ILC2 inhibition. Combination of IL-33 with PD-1 blockade increased tumor ILC2 and eosinophil recruitment and improved anti-tumor protection. This reveals a mechanism to improve ILC2 function and highlights that, in this setting, immune checkpoint blockade alone is unlikely to fully rescue anti-tumor responses. Thus, tailored reactivation of ILC2s in this setting can strongly influence tumor regression.

GM-CSF has recently been identified as a key cytokine produced by ILC3 important to maintain intestinal homeostasis through cross-talk between macrophages, regulatory T cells and ILC3s 35 in inflammation 36 . It is also produced by NK cells that can exert powerful antitumor responses 37 and conversely drive inflammation to exacerbate inflammatory arthritis 30 . We now show that ILC2s express high levels of GM-CSF in melanoma tumors. Although GM-CSF has previously been identified as potent in promoting anti-tumor responses, its therapeutic benefit in melanoma has remained controversial 38 , but recently it has been shown using genetically modified herpes simplex virus type 1-based oncolytic immunotherapy, talimogene laherparepvec to be important 39 . This virus produces large amounts of GM-CSF in tumors and induces both potent local and systemic anti-tumor immune responses in melanoma patients 40 . This suggests that endogenous levels of GM-CSF within tumors are not usually sufficient to efficiently harness immune control of melanoma tumor development. Using IL-33 to drive ILC2 amplification, intratumor accumulation and increased GM-CSF, however, provides a strategy to enhance the antitumor response. This mechanism also increased eosinophil tumor recruitment and survival and enhanced eosinophil cytotoxic function. GM-CSF forms a critical checkpoint in synergizing with ILC2-derived cytokines such as IL-5 to drive eosinophil proliferation and function 18, 41 . However, poor understanding of the mechanisms that underpin the roles of eosinophils in anti-tumor immunity have limited targeting approaches for clinical practice. IL-33 stimulation itself can directly affect eosinophil anti-tumor functions through adhesion molecules such as CD11b and ICAM1 and enhance eosinophil degranulation and cytotoxicity to potentiate killing of tumor cells 15, 18 . In addition, using RNA sequencing in colorectal cancer, we previously revealed that eosinophils were critical for tumor rejection and displayed an interferon-dependent profile and cytotoxic machinery similar to CD8 + T cells 42 .

Among innate immune cells, DCs, particularly type 1 conventional DC (cDC1), are critical for tumor elimination 43 . They trigger potent anti-tumor responses and are necessary to prime tumor antigen-specific T cells. Using ILC2-deficient mice, we found reduced tumorinfiltrating CD103 + cDC1 associated with a decrease of CD8 + T cells in melanoma tumors. Similar observations have recently been reported in pancreatic tumors, suggesting that ILC2 -though their capacity to produce GM-CSF or CCL5 -may potentially recruit and activate intratumoral cDC1, which in turn increase the function and accumulation of tumor antigen specific CD8 + T cells 6 . However, given that the maintenance and function of CD103 + DC, as well as CD103 expression itself, are driven in part, by the presence of GM-CSF 44 , the use of the β integrin CD103 for intratumoral cDC1 identification might suboptimal. Indeed, reduced CD103 expression on DCs may occur as intratumoral GM-CSF expression occurs in mice deficient in ILC2s which normally express the highest levels of GM-CSF in three different melanoma models examined. Thus, further analyses will be required to ascertain the direct contribution of ILC2s to the recruitment and activation of intratumoral cDC1 tumor antigen specific CD8 + T cells.

We and others discovered that PD-1, mainly known as a T cell inhibitory receptor, is also expressed on bone marrow ILC progenitors 28, 45 and mature ILC subsets found in peripheral tissues 46 . Tissue-resident ILC2s constitutively express PD-1 thereby influencing normal ILC2 function and strongly impacting outcomes in infection and cancer 6, 45, 47 . Similar to the findings of Moral et al 6 in pancreatic cancer, we observed that PD-1 expression negatively regulates melanoma tumor ILC2 accumulation and effector function, resulting in impaired ILC2-dependent anti-tumor responses. In addition, we found that IL-33-mediated ILC2 proliferation and enhanced GM-CSF production were both associated with increased PD-1 expression, aligned to previous reports 6, 47 . These findings suggest that ILC2-mediated GM-CSF expression may be dampened as PD-1 expression increases following IL-33 injections, reducing the beneficial impact of IL-33-mediated ILC2 anti-tumor functions. However, these effects are mitigated by co-injection of the anti-PD-1 antibody to remove the inhibitory signals. While we found an increase in adaptive CD8 + T cells in the tumor microenvironment, we also observed the recruitment and accumulation of ILC2s and eosinophils in tumors and peripheral organs. Thus both the innate and adaptive immune arms are synergistically harnessed in the context of combination therapies driving potent anti-tumor responses. More recently, the combination of the GM-CSF-producing oncolytic virus with immune checkpoint inhibitors has demonstrated increased objective response rate and anti-tumor activity in melanoma 48, 49 . In particular, combination with anti-PD-1 antibody led to improved immune checkpoint therapy and increased anti-tumor immunity 48 .

Thus, similar to IL-33 treatment, non-redundant and complementary anti-tumor immune functions involving both the innate and adaptive arms may be selectively reinvigorated to bolster anti-tumor immunity. Whether similar observations are seen when GM-CSFproducing oncolytic virus is combined with anti-PD-1 immunotherapy remains unknown, but resistance to immune checkpoint blockers has recently been shown to be overcome by intralesional talimogene laherparepvec injections in melanoma patients 50 .

Collectively, our findings reveal that tumor-infiltrating ILC2s establish the framework for secreted signals, cellular recruitment and cooperation between innate immune cells to unleash anti-tumor functions ( Supplementary Fig. 11 ). Thus, targeting this innate ILC2eosinophil axis and adaptive lymphoid cells are necessary to fully capitalize on the immune system and help design new therapeutic combinations in melanoma. We propose that mapping the expression of ILC2s and eosinophils in tissues may provide a strong prognostic factor of patient outcomes and warrants additional studies in large cohorts for clinical application of our findings. 53 ), IL7r iCr eRora fl/fl (ref. 53 ), Rorc(γt) GFP/GFP (ref. 27 ), ID2 GFP/GFP (ref. 54 ), Eomes mCherry (ref. 55 ), Pdcd1 -/-(ref. 56 ), Csf2 -/-(B6.129S-Csf2 tm1Mlg /J, ref. 57 ), Tg(Cd3d-Il5)NJ.1638 (ref. 58 ) and eosinophil-deficient ΔdblGATA (ref. 59 ) and PHIL (Tg(Epo-DTA)#Nal, ref. 60 

For depletion of ILC2 in vivo, ICOS-T mice and C57BL/6J control mice were treated intraperitoneally with 0.5mg of recombinant mIL-33 (PeproTech) and/or 4ng/g of body weight of diphtheria toxin (Sigma) concomitantly (Extended Data Fig. 4 ). Control animals received PBS only. C57BL/6J mice were treated intraperitoneally with 0.5μg of recombinant mIL-33 (PeproTech) and/or 250μg of anti-PD-1 (clone RMP1-14, BioXcell) or received control ratIgG2a isotype antibody (Clone 2A3, BioXcell) or PBS (Fig. 8 ).

Tumor inoculation, induction and monitoring SM1WT1, B16-OVA and Ret tumor inductions-Syngeneic C57BL/6J mice were shaved and then implanted with 5×10 5 SM1WT1, B16-OVA or Ret cells intradermally.

Spontaneous melanoma induction in vivo-Immediately prior to tumor induction, the flank of BRAF CA ;PTEN loxp ;Tyr::CreER T2 mice was shaved. 2μl of a 5mM 4hydroxytamoxifen solution was placed on the skin of mice to delete PTEN in tyrosinaseexpressing cells 22 . This is associated with the expression of a constitutive active form of BRAF that together leads to the development and clinical appearance of melanomas after approximately 30 days after topical treatment (Extended Data Fig. 1a) . In both models, tumor size was monitored every 2 to 3 days and ethical end points were reached when (i) tumor size reached 200 mm 2 or (ii) tumor site showed ulceration. Spleen and lymph nodes-Single cell suspensions were generated from spleen and lymph nodes by dissociating tissues using 70μm filters. Red blood cells from the spleen were removed using a hypotonic solution and samples washed and resuspended in cold FACS buffer prior to analyses.

Single 

Bone marrow cells were isolated from the long bones, hips and sternum. Cleaned bones were crushed with mortar and pestle in PBS to create a single cell suspension. Cells were then filtered through 70μm cell strainers. Intestinal ILC2 were identified as: CD45 + CD3 -CD19 -TCRβ -CD11b -NK1.1c-kit -Sca-1 + KLRG1 +/or CD45 + CD3 -CD19 -TCRβCD11b -NK1.1c-kit -CD90.2 + CD127 + KLRG1 + . 2.5-8.5×10 3 purified cells were cultured in 96 well plates with 40ng/ml rhIL-7 and rmIL-33 (both from PeproTech) in complete media. After two to five days of culture, cells were collected and stained to assess surface and intracellular cytokine expression. The ILC2-conditioned media was collected to supplement eosinophil cultures at a 1:1 ratio (Supplementary Fig. 9 ).

Eosinophils-Eosinophils were isolated from the spleens of naïve Ly5.1 +/+ mice by magnetic separation enrichment followed by flow cytometric sorting. Single cell suspensions of spleen were resuspended in MACS Buffer and then stained with an anti-Siglec-F (E50-2440, BD Biosciences, 1/100 dilution) antibody for 30 minutes on ice. Cell suspensions were washed and incubated with α-PE magnetic microbeads (Miltenyi Biotec) for 30 minutes on ice prior to enrichment of the Siglec-F-binding fraction using LS columns (Miltenyi Biotech). Live splenic eosinophils were then identified and purified as SSCA hi Siglec-F + Ly6Gcells. After washing cells with complete media, 5×10 4 purified eosinophils were cultured in complete media in 96 well plates supplemented with or without ILC2-conditioned media (ratio 1:1). After overnight culture, cells were harvested, washed twice in PBS before resuspension in RLT + (RNA later + β-Mercaptoethanol) buffer and stored at -80°C until RNA extraction.

Eosinophils were isolated from peritoneum of Il5 Tg mice using magnetic separation. Peritoneal cells were isolated by washing the peritoneal cavity of Il5 Tg mice with sterile PBS. Eosinophils were isolated using negative selection with anti-Thy1.2 and anti-B220 Dynabead conjugated antibodies. Eosinophil purity and viability was determined using CD45, Siglec-F and DAPI antibody staining by flow cytometry. Eosinophils were used only >90% purity and viability. Eosinophils were incubated with DMEM supplemented with increasing concentrations of GM-CSF (PeproTech) and images were recorded every 15 min using IncucyteZOOM (Essen BioScience) live imaging. Analysis was conducted using IncucyteZoom2016B analysis software, normalization was performed according to maximal PI-positive object count to calculate the percentage of dead cells.

Total RNA extraction and genomic DNA removal were performed using the RNeasy Plus Micro Kit (Qiagen). First-strand cDNA was generated from total RNA using iScript™ Reverse Transcription Supermix for RT-qPCR Genomics protocols using the Chromium™ Single Cell 3' Library and Gel Bead Kit (v2). Briefly, sorted leukocytes were suspended at a concentration of 1 × 10 3 cells/μl and then loaded onto 10X Chromium™ Single Cell 3' Chips to be encapsulated in Gel Beads in Emulsion (GEM). Then PolyA barcoded cDNA was generated after incubation with GEM at 53°C for 45 minutes using a Thermocycler. After cleaning, cDNA was amplified for 10 cycles, enzymatically fragmented, end repaired, A-tailed and double-sided size selected. An adaptor was ligated and then each library was indexed by adding a sample index tag by PCR for 14 cycles. A second double-sided selection was performed to obtain an average of 445 and 410bp for the two samples. Libraries were sequenced on an Illumina NextSeq platform to a depth of 0.2 million reads/cell.

Bioinformatics analyses-Reads from each sample were processed using 10× Genomics Cell Ranger software (version 3.0.2). Cellranger mkfastq was used to demultiplex cell barcodes and convert BCL-format Illumina reads in each flowcell directory into FASTQ files. Reads were then mapped to mouse reference genome GRCm38. Mapped reads were deduplicated and counted to Ensembl genes to produce UMI (Unique Molecular Identifier) counts for each gene in each cell. On average between 1 × 10 3 to 2 × 10 3 genes were identified for each cell. Subsequent analyses were performed in R (v3.6.0). Outlier cells were removed if they (i) had < 200 or > 2,500 genes expressed, (ii) had more than 5% of mitochondrial gene content or (iii) genes failed to be detected in >3 cells. UMI counts of genes were converted to log 2 count-per-million (log 2 -CPM) values, with a prior count of 5 added to raw counts to avoid log transformation of zero. The t-distributed stochastic neighbor embedding (t-SNE) technique was used to identify different clusters. Immune cell populations were mapped using SingleR 29 through the ImmGen database which also allows mapping of small numbers of cells 63, 64 . Z-scores in those dot plots, which show gene expression and the proportion of cells expressing targeted genes, were calculated using average log 2 -CPM values of each gene computed over all the cells in each cell type. Single cell RNA sequencing data from this study have been deposited in the Gene Expression Omnibus (GEO) repository under accession number GSE149615.

Data analyses and representations were performed either with the R software or Prism (GraphPad version 7.0 or 8.0, San Diego, CA, USA). Statistical analyses were two-sided. In all cases, confidence intervals were reported at a nominal level of 95%. For more than two groups, statistical analyses were performed using ANOVA followed by Tukey's multiple comparison test or pairwise comparisons with Bonferroni adjustments. Otherwise, for two groups, statistical analyses were performed using the paired or unpaired Student's t tests.

Results are shown as the mean ± s.e.m. Correlations between two variables were assessed using non-parametric Spearman correlation tests. Tumor growth experiments were analysed with TumGrowth software (https://kroemerlab.shinyapps.io/TumGrowth/) with default settings at the exception of the original tumor measurements that were log transformed before linear mixed-effect modelling. Cox proportional hazards modelling were applied when assessing the impact of the genotype on mice survival. p-values were two-sided with 95% confidence intervals and considered significant at p < 0.05. Germany) according to the manufacturer's instructions. All steps were performed at room temperature unless indicated. Briefly, heat-induced epitope retrieval (HIER) by incubating tissue sections in 1mM EDTA buffer, pH 8.0 at 125°C for 3 minutes followed by blocking buffer for 10 minutes. Slides were incubated in the primary antibody for 30 minutes, followed by Opal polymer HRP Ms+Rb for 10 minutes. The fluorescent signal was introduced using reactive fluorophores by incubating for 10 minutes. The antibody was stripped using HIER before applying the next primary antibody. Endogenous peroxidase in tissues were blocked using 3% hydrogen peroxide solution after incubation with the first primary antibody. For the last antibody, OPAL TSA-DIG were applied after Opal polymer HRP Ms+Rb step and before Opal Polaris 780 fluorophore. After the final antigen retrieval using HIER, slides were washed twice before staining nuclei with 4′,6-diamidino-2phenylindole (DAPI), and mounted using ProLong™ Glass Antifade Mountant (Thermo Fisher Scientific, Waltham, Massachusetts, United States). All slides were subsequently imaged on a Vectra Polaris™ quantitative pathology imaging system (Akoya Biosciences). High-powered images at 20X were selected using Phenochart (Akoya Biosciences) and imported into inForm® Software v2. anti-CD68-171Yb (Y1/82A, Fluidigm, 1:1,000). After washing in perm-wash buffer twice, the pellet was resuspended in iridium intercalator (EM Sciences) at 0.1μM in 2% paraformaldehyde in PBS and stored up to 48 hrs in the fridge before acquisition. Cells were washed in CSM and twice in deionized water (MilliQ, Merck) before loading onto Helios instrument (Fluidigm) for acquisition. Antibodies not purchased from Fluidigm were purchased from the listed sources, and metal conjugated in house using X8 Multi-Metal Labelling Kit (Fluidigm). Informed consent was obtained from all patients.

For the isolation of human ILC2, blood or Buffy coats were obtained from healthy donors (Ethics approval number: HREC/2019/QMS/55385, University of Queensland Metro North Ethic Committee). PBMCs were isolated by Ficoll-Paque (GE Healthcare). ILC2 were MACS separated according to protocol using human ILC2 isolation kit (lineage -, CRTH2 + , Miltenyi). Cells were then stained and FACS sorted for purity with following antibodies 1, BD Horizon) . ILC2 were defined as live CD45 + lineage -CD127 + CD56 -CD16-CRTH2 + . Freshly sorted ILC2 were cultured for 2 days with IL2 (5ng/ml, PeproTech) or IL2 and IL-33 (5ng/ml and 10ng/ml (Miltenyi), respectively) in complete media consisting of RPMI 1640 supplemented with: 10% heatinactivated human AB + Serum, 2mM L-Glutamine, 1mM Sodium Pyruvate, 100U/ml penicillin, 100μg/ml Streptomycin (300-2000 cells/well). After 2 days of culture, supernatant was harvested and stored at -80 degrees. Cells were freshly stained with anti-PD-1 antibody and analysed by flow cytometry. GM-CSF production was analysed by using the BD Biosciences cytometric bead array flex set for human GM-CSF according to manufacturer's instructions.

RNA was isolated and purified from 10μm tissue sections using the RNeasy FFPE kit (Qiagen) according to the manufacturer's instructions. 1μl of RNA from each sample was tested for quality using a High Sensitivity RNA TapeStation assay (Agilent) with a DV200 cut-off of > 50% for downstream analysis. 150 ng total RNA from each sample was analysed using the Nanostring platform using the nCounter PanCancer Immune Profiling Panel. Downstream normalisation and gene quantification were performed using nSolver Analysis Software v4.0. The raw counts were read from RCC files using CRAN package nanostringr. Sample-specific library size factors were estimated from negative control genes using calcNormFactors() in edgeR. The estimated normalization factors were then used to compute log-CPM values, which were then used an input to ILC2 prediction model (classifier).

ILC2-Raw read counts for single cell RNA-sequencing of human tonsil innate lymphoid cells (ILCs), including ILC1, ILC2, ILC3 and NK cells were obtained from a previously published study available under accession GSE70580 65 . Cells of low quality with more than 5% mitochondrial contamination and genes expressed in less than 5% of the cells were filtered out. Read counts were normalized and the top 5,000 highly variable genes were identified using scran R/Bioconductor package. A classifier was trained to learn the ILC2 gene expression signature using 241 genes (features) based on highly variable genes overlapping a panel of 730 immune genes on 80% of the data, while the rest of the data was used as the test dataset to tune the model parameters. An Extreme Gradient Boosting (XGboost) classifier was trained using tree boosting, maximum tree depth of 5, learning rate of 0.05, a binary logistic objective and 9 rounds of iteration using xgboost R package. The classifier was also validated on an independent dataset of mouse single cells of wild-type skin ILC2 obtained from GSE117568 66 . The classifier was then applied to TCGA primary and metastatic SKCM cohorts, where RNAseq profiles were transformed to log2 Counts per Million (CPM) and centered and scaled by gene expression values in the training data.

Eosinophil-The Eosinophil classifier was trained on Eosinophil population profiles as part of a Homo Sapiens micrroarray dataset of purified hematopoietic stem and progenitor cells and lymphocyte populations available under accession GSE24759 67 . A Support Vector Machine classifier with linear kernel was trained on this dataset using e1071 R package, leaving all other parameters in their default settings. The classifier was validated on an independent Eosinophil dataset available on GSE115736 68 . The correlation between ILC2/ type 2 immune cells, eosinophils and gene expression was determined using the Spearman correlation implemented in base R software. and the mean of three biological replicates. Flow cytometric contour plots depict a representative analysis performed at day 5 of culture. f, GM-CSF concentration in culture supernatant of purified human ILC2 isolated from the blood of three healthy donors and stimulated with rIL-2 (5 ng/ml) or rIL-2+rIL-33 (5 ng/ml and 10 ng/ml, respectively). ILC2 were identified as Live + CD45 + lin -(TCRαβ -TCRγδ -CD14 -CD3 -CD19 -CD34 -FcεRI -CD123 -CD303 -CD15 -CD33 -CD11c -CD56 -CD16 -) CD127 + CRTH2 + . Data show the mean GM-CSF production of 3 healthy donors pooled from two independent experiments. N.D., not detected. g, Histograms (left panel) and frequencies (right panel) of PD-1 expression on wild-type and Pdcd1 -/-ILC2 (2.5 × 10 3 cells/well) cultured in vitro for 2 and 5 days in complete media supplemented with rIL-7 or rIL-7+rIL-33 (all 40 ng/ml). Data show the mean of three biological replicates. h, Representative flow-cytometric contour plots showing PD-1 expression on purified human ILC2 isolated from blood of healthy donors after two days of stimulation with rIL-2 (5 ng/ml) or rIL-2+rIL-33 (5 ng/ml and 10 ng/ml, respectively). ILC2 were identified as in f.

One representative healthy donor out of two yielding similar results is shown. b-f, Statistical analyses were performed using paired Student's t-test. p-values are indicated.

Refer to Web version on PubMed Central for supplementary material. a, Frequency of dendritic cells (DC, CD45 + CD3ε -CD19 -CD11b + CD11c hi MHC class II hi ) and monocytes (CD45 + CD3ε -CD19 -CD11b + Siglec-F -Ly6G -Ly6C hi CD64 +/-). b, Flow cytometric contour plots (upper panels)_and frequency (lower panels) of neutrophils (CD45 + CD3ε-CD19 -CD11b + Siglec-F -Ly6G + ) and eosinophils (CD45 + CD3ε -CD19 -CD11b + Ly6G -SiglecF + ) from Rag1 -/-, Rag2 -/-Il2rg -/and Rag2 -/-Il2rg -/mice reconstituted with ILC2 progenitors (ILC2p, 2.5×10 3 cells/mouse) from GM-CSF deficient (Csf2 -/-) and wildtype (WT) control mice analyzed 7 weeks after transfer of ILC2p. Data pooled from 2 a, Single cell RNA sequencing analyses of tumor-infiltrating leukocytes purified from BRAF CA ;PTEN loxp ;Tyr::CreER T2 tamoxifen-induced tumors showing differentially expressed genes coding for selected immune checkpoint and costimulatory molecules (yaxis) grouped according to T cell and ILC subsets (x-axis) as identified in Fig. 3a . b, Flow cytometric contour plots (left panels) and frequency (right panel) of PD-1 expression on T cells and ILC2 isolated from BRAF CA ;PTEN loxp ;Tyr::CreER T2 tumor-bearing mice. Data pooled from 5 independent experiments (n=29 tumors). c, Comparison of the frequency of 

Tissue-resident memory CD8(+) T cells promote melanoma-immune equilibrium in skin

Tissue-resident memory T cells in tissue homeostasis, persistent infection, and cancer surveillance

Situ Mapping of Innate Lymphoid Cells in Human Skin: Evidence for Remarkable Differences between Normal and Inflamed Skin

Activated innate lymphoid cell populations accumulate in human tumour tissues

Polarization of ILC2s in peripheral blood might contribute to immunosuppressive microenvironment in patients with gastric cancer

ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity

Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis

Targeting of IL-4 and IL-13 receptors for cancer therapy

Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair

The multiple roles of amphiregulin in human cancer

ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence

Type 2 Innate Lymphocytes Actuate Immunity Against Tumours and Limit Cancer Metastasis

Type 2 Innate Lymphoid Cells Protect against Colorectal Cancer Progression and Predict Improved Patient Survival. Cancers (Basel)

Tumor-Derived Lactic Acid Contributes to the Paucity of Intratumoral ILC2s

IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanomabearing mice through eosinophils

ILC2-driven innate immune checkpoint mechanism antagonizes NK cell antimetastatic function in the lung

Type 2 Innate Lymphoid Cells Impede IL-33-Mediated Tumor Suppression

A new dawn for eosinophils in the tumour microenvironment

Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy

Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma

Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells

An essential function for the nuclear receptor ROR gamma t in the generation of fetal lymphoid tissue inducer cells

Deciphering the Innate Lymphoid Cell Transcriptional Program

Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage

NK cell-derived GM-CSF potentiates inflammatory arthritis and is negatively regulated by CIS

RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis

Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma

Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis

ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation

Harnessing innate immunity in cancer therapy

Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma

Quantitative analysis of long-term virus-specific CD8+-T-cell memory in mice challenged with unrelated pathogens

Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment

Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity

Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer

Dissecting the tumor myeloid compartment reveals rare activating antigenpresenting cells critical for T cell immunity

GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells

Single-cell RNA-seq identifies a PD-1hi ILC progenitor and defines its development pathway

Rethinking immune checkpoint blockade: 'Beyond the T cell

PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma

Following the development of a CD4 T cell response in vivo: from activation to memory formation

Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor

MHCII-Mediated Dialog between Group 2 Innate Lymphoid Cells and CD4(+) T Cells Potentiates Type 2 Immunity and Promotes Parasitic Helminth Expulsion

Id2 expression delineates differential checkpoints in the genetic program of CD8alpha(+) and CD103(+) dendritic cell lineages

CCR2 defines in vivo development and homing of IL-23-driven GM-CSFproducing Th17 cells

PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues

Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis

Expression of IL-5 in thymocytes/T cells leads to the development of a massive eosinophilia, extramedullary eosinophilopoiesis, and unique histopathologies

Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo

Defining a link with asthma in mice congenitally deficient in eosinophils

Transgenic mouse model for skin malignant melanoma

QuPath: Open source software for digital pathology image analysis

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis

The heterogeneity of human CD127(+) innate lymphoid cells revealed by single-cell RNA sequencing

Tissue signals imprint ILC2 identity with anticipatory function

ILC2-dependent anti-melanoma immunity

Tumor growth curves (a, left panel), tumor size at day 13 post tumor inoculation (a, middle panel) and survival (a, right panel) are shown. Data pooled from 3-4 independent experiments with 4-7 mice/group/experiment (C57BL/6J, n=24 mice; Rag1 -/-, n=25 mice; Rag2 -/-Il2rg -/-, n=15 mice). b, Tumor growth curves (left panel) and tumor size at day 14 (right panel) in NKp46 iCre/+ Mcl1 +/+ control and NKp46 iCre/+ Mcl1 Δ/Δ mice inoculated with Ret tumor cells

2-7 mice/genotype/experiment). c, Tumor growth curves (left panel) and tumor size at day 17 (right panel

Rorc(γt) GFP/+ → Ly5.1 +/+ , n=12 mice; Rorc(γt) GFP/GFP → Ly5.1 +/+ , n=12 mice; 6 mice/genotype/experiment). d, Tumor growth curves (left panel) and day 12 tumor size (right panel) in Il7r +/+ Rora fl/fl littermate control and Il7r Cre/+ Rora Δ/Δ mice inoculated with Ret tumor cells

Tumor growth curves (upper panels) and day 12-13 tumor size (lower panel) of Ret tumor cells injected in C57BL/6J, Rag1 -/-mice and Rag2 -/-Il2rg -/-mice, or Rag2 -/-Il2rg -/-recipients reconstituted for 6 to 10 weeks with purified bone marrow-derived ILC2p (2-2.5×10 3 cells/ mouse), αLP (2-3×10 3 cells/mouse) or CLP (5×10 3 cells/mouse). Data are pooled from 4 independent experiments (C57BL/6J, n=24 mice; Rag1 -/-, n=22 mice; Rag2 -/-Il2rg -/-, n=11 mice; Rag2 -/-Il2rg -/-+ ILC2p, n=20 mice; Rag2 -/-Il2rg -/-+ αLP, n=18 mice; Rag2 -/-Il2rg -/-+ CLP, n=12 mice; 2-8 mice/group/experiment). a-e, Each circle represents one mouse and data show the mean+s.e.m. Tumor growth (a-d

3 independent experiments (C57BL/6J, n=16 mice and Csf2 -/-, n=17 mice

Rag1 -/-, n=12 mice; Rag2 -/-Il2rg -/-, n=6 mice; Rag2 -/-Il2rg -/-+ WT ILC2p, n=10 mice; Rag2 -/-Il2rg -/-+ Csf2 -/-ILC2p, n=7 mice; TumGrowth. c-f, Each dot shows one mouse and data show the mean ± s.e.m. c, d and g, Statistical analyses were performed using paired Student's t test

Author manuscript; available in PMC

Individual mice are colored by experimental group; linear regression curve is overlaid. Correlation assessed using non-parametric Spearman's correlation test. Data show representative plots (c) or are pooled from 2 independent experiments (n=2-6 mice/ group/experiment) (d and e). f, Cumulative tumor growth (left panel) and tumor size (day 16, right panel) in C57BL/6J and PHIL mice inoculated with Ret tumor cells

Statistical analyses were performed by using TumGrowth. g, Quantitation and h, hematoxylin and eosin staining of B16-F10 melanoma lung metastasis (day 16) and lung tumor burden (right panel) in wild-type and eosinophil-deficient ΔdblGata mice. Data pooled from 2 independent experiments (g, C57BL/6J, n= 16 mice; ΔdblGata

or unpaired Student's t tests (g and h). p-values are indicated. Data are shown as the mean ± s.e.m. independent experiments (Rag1 -/-, n=12 mice; Rag2 -/-Il2rg -/-, n=9 mice; Rag2 -/-γc -/-+ WT ILC2p, n=10 mice; Rag2 -/-Il2rg -/-+ Csf2 -/-ILC2p, n=11 mice; 4-6 mice/group/ experiment). c, Quantitative Gata2, Epx, Ear1 and Ear2 expression normalized to Gapdh in splenic eosinophils cultured overnight in complete media, or complete media + ILC2-conditioned media (ratio 1:1) (n=6 mice/experiment. Each dot represents one biological or technical replicate. Data pooled from 2 independent experiments with 1-4 biological or technical replicates/genotype/experiment. d, Effect of GM-CSF on eosinophil survival. Peritoneal eosinophils from IL-5Tg mice were cultured (40 × 10 3 /well, in triplicate) in serum free media with or without increasing concentrations of GM-CSF or complete media for 16 hours and dead cells (Propidium Iodide + ) was quantitated using IncucyteZOOM live imaging. Data show one representative experiment out of 2 performed with technical replicates. a-c, Each dot represents one mouse sample. a-d, Statistical analyses were performed using ANOVA followed by Tukey's multiple comparison test (a and b

Singlet immunostaining from the composite image (scale bar 50 μm). g, Frequency of PD-1-expressing T cells (CD45 + CD3 + PD-1 + , n=18) and ILC2 (CD45 + CD3 -GATA3 + PD-1 + , n=10) in primary melanoma tumors. h, Comparison of the frequency of PD-1 + ILC2 relative to PD-1 + T cells. i, Comparison of the frequency of PD-1 + T cells or PD-1 + ILC2 relative to PD-L1 + melanoma cells (SOX10 + PD-L1 + ). b-e and g-i, Each dot represents one mouse (b-e) or human sample (g-i). b, d and g, Data show mean ± s.e.m. c, e, h and i, Correlations were assessed using non

1 bone marrow chimeras were injected with Ret tumor cells 6 weeks after reconstitution. e, Experimental design. f, Tumor growth (left) and tumor size (day 18, right). Data pooled from 2-3 independent experiments

Frequency of CD8 + T cells (left) and ILC2 among bone marrow-derived cells in the spleen, LN and tumor. Data show one experiment (n=6 mice). h, Ret tumor growth in C57BL/6J, Rag1 -/-mice and Rag2 -/-Il2rg -/-mice, or Rag2 -/-Il2rg -/-mice reconstituted with wildtype (WT) or Pdcd1 -/-purified bone marrow-derived ILC2p six weeks prior to injection. Data show one experiment (C57BL/6J, n=6 mice ; Rag1 -/-, n=6 mice; Ragc -/-Il2rg -/-, n=3 mice; Rag2 -/-Il2r -/-+ wildtype ILC2p, n=5 mice; Rag2 -/-Il2rg -/-+ Pdcd1 -/-ILC2p, n=5 mice). (a-d, f and g) Each circle represents one mouse. (a-d,f-h) Data show mean ± s.e.m. (b-d) Statistical analyses were performed using unpaired Student's t-test. (a and f) Tumor growth statistical analyses were performed using TumGrowth. p-values are indicated. between treatment and control group in tumors, spleen, contralateral (cLN) and tumordraining (tdLN) lymph nodes of injected mice. *statistical significance between experimental and control groups. h, Frequency of proliferating

Individual data points are colored by group. b,e,f,h,j and k, Data show the mean ± s.e.m. b,e,f,h,j,k and m, Each dot shows one mouse. b-m, Data are pooled from 4 independent experiments (Control, n=21; Anti-PD-1, n=23; rIL-33, n=23; Anti-PD-1+rIL-33, n=22) (b), 2 independent experiments (Control, n=11; Anti-PD-1, n=11-12; rIL-33, n=11; Anti-PD-1+rIL-33, n=9-11) (e-h, and j-l) or represents one experiment (d,i, and m) with 4-6 mice/experimental group/experiment. b, Tumor growth statistical analyses were performed using TumGrowth. e,f,h,j,k, Statistical analyses were performed using a Student's t-test (h) or ANOVA with Tukey's multiple comparison test (e,f,j,k,g,l). m, Correlations were assessed using non-parametric Spearman's correlation test

Single cell RNA sequencing data that support the findings of this study have been deposited with the Gene Expression Omnibus (GEO) repository under accession number GSE149615. Source code for statistical learning models is publicly available at: https://github.com/ DavisLaboratory/Jacquelot_2021_reproducibility. All the data to evaluate the conclusions in this paper are present either in the main text, extended data or in supplementary materials.population that express each gene.